Literature DB >> 28114248

From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

Sarah A Weiss1, Harriet M Kluger.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28114248      PMCID: PMC5526070          DOI: 10.1097/PPO.0000000000000244

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


× No keyword cloud information.
  6 in total

1.  Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.

Authors:  Audrey Andrews
Journal:  Am Health Drug Benefits       Date:  2015-08

Review 2.  Historical review of melanoma treatment and outcomes.

Authors:  Carrie Lee; Frances Collichio; David Ollila; Stergios Moschos
Journal:  Clin Dermatol       Date:  2013 Mar-Apr       Impact factor: 3.541

3.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

4.  A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Authors:  E M Hersh; M Del Vecchio; M P Brown; R Kefford; C Loquai; A Testori; S Bhatia; R Gutzmer; R Conry; A Haydon; C Robert; S Ernst; J Homsi; J J Grob; K Kendra; S S Agarwala; M Li; A Clawson; C Brachmann; M Karnoub; I Elias; M F Renschler; A Hauschild
Journal:  Ann Oncol       Date:  2015-09-26       Impact factor: 32.976

Review 5.  Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges.

Authors:  Francesca Tartari; Matteo Santoni; Luciano Burattini; Paola Mazzanti; Azzurra Onofri; Rossana Berardi
Journal:  Cancer Treat Rev       Date:  2016-06-07       Impact factor: 12.111

6.  Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Authors:  Ajjai Alva; Gregory A Daniels; Michael K K Wong; Howard L Kaufman; Michael A Morse; David F McDermott; Joseph I Clark; Sanjiv S Agarwala; Gerald Miletello; Theodore F Logan; Ralph J Hauke; Brendan Curti; John M Kirkwood; Rene Gonzalez; Asim Amin; Mayer Fishman; Neeraj Agarwal; James N Lowder; Hong Hua; Sandra Aung; Janice P Dutcher
Journal:  Cancer Immunol Immunother       Date:  2016-10-06       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.